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Ste´phane Fouquet1,2,3, Shu-Fang Wang1,2,3, Eduardo Marinho4, David Farhi7,8, Maryle`ne Garcette1,2,3,
Simon Jacobelli1,2,3,8, Alexandre Rouquette9, Agne`s Carlotti9, Ange´lique Girod10, Armelle Pre´vost-Blondel1,2,3,
Alain Trautmann1,2,3, Marie-Franc¸oise Avril1,2,3,8 and Nade`ge Bercovici1,2,3
Programmed death-1 (PD-1) is involved in T-cell tolerance to self-antigens. For some cancers, it has been
suggested that the expression of a ligand of PD-1, namely PD-L1, could contribute to tumor escape from
immune destruction. Nevertheless, the relationship between PD-1 expression on tumor-infiltrating
T lymphocytes (TILs), disease stage, and TIL responsiveness is still poorly documented. In this study, we show
that freshly isolated CD4þ and CD8þ TILs express substantial levels of PD-1 in primary melanomas. The
expression of PD-1 was further increased at later stages in distant cutaneous metastases, especially on CD8þ
TILs. The expression of PD-1 ligands was frequent only in metastases, on both tumor cells and tumor-derived
myeloid cells. TILs isolated from these cutaneous tumors are poorly reactive ex vivo, with blunted calcium
response and IFN-g production after TCR stimulation. Surprisingly, in distinct parts of a primary melanoma,
either invasive or regressing, we show that TILs similarly express PD-1 and remain dysfunctional. The
expressions of PD-1 and PD-L1 in metastatic melanoma lesions could be considered as witnesses of an
unsuccessful anti-tumoral immune response, but the direct involvement of PD-1 in the severity of the disease,
and the importance of TILs in tumor regression, remain to be established.
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INTRODUCTION
Infiltration of primary melanoma by CD8 T cells is associated
with a better prognosis (Piras et al., 2005), indicating that T
lymphocytes contribute to control tumor progression. How-
ever, despite recognition of melanoma cells (Romero et al.,
1998; Dunbar et al., 2000), T cells primed against tumor
antigens are unable to efficiently control tumor growth and
dissemination of metastases in patients. In particular, to
explain the lack of efficiency of tumor-infiltrating T lympho-
cytes (TILs), it is believed that TILs that reside in tumors
acquire functional defects that prevent anti-tumor activity.
Low production of IFN-g or tumor necrosis factor-a, and the
absence of cytotoxic effector molecules such as granzyme B
or perforin often characterize anti-tumor CD8 T cells found in
metastatic lymph nodes or, although less frequently reported,
in non-lymphoid tumor lesions (Zippelius et al., 2004).
Therapeutic vaccinations can increase the frequency of anti-
tumor-specific T cells (Banchereau et al., 2001; Bercovici
et al., 2008) but T cell-infiltrating tumor lesions of treated
patients are poorly reactive compared with peripheral blood
T cells (Appay et al., 2006).
Programmed death-1 (PD-1) is one of the receptors that,
like cytotoxic T-lymphocyte antigen 4, has been implicated
in the control of peripheral tolerance to self-antigens and may
be involved in dampening anti-tumor T-cell responses (Keir
et al., 2008). PD-L1 and PD-L2 are the two ligands known to
bind to PD-1. PD-L1 is expressed by many cell types,
whereas PD-L2 expression is restricted to hematopoietic cells
in a physiological situation. Deregulations in tumor cells,
including phosphatase and tensin homolog mutations (Parsa
et al., 2007), can lead to the expression of PD-L1 or PD-L2 in
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these cells. In humans, indirect evidence supports a role for
the PD-1/PD-L1 pathway in tumor-immune escape. Indeed,
an association between PD-L1 expression of tumor samples
and poor survival of cancer patients has been demonstrated
for various cancers (Thompson et al., 2006). This indicates
that the presence of PD-L1 at the time of primary tumor
development has later consequences (i.e., after the primary
tumor has been removed) on the appearance or control of
metastasis dissemination. In renal cell carcinoma, the
expression of PD-1 in situ is of poor prognosis (Thompson
et al., 2007). A similar analysis in melanoma patients is still
missing. Mackensen and colleagues (Blank et al., 2006) have
shown that an anti-PD-L1 antibody can improve anti-tumor
TCR-transgenic T-cell response in vitro, although the effect
was relatively modest. This suggests that the PD-1 expression
on TILs can limit its in vitro reactivity, a notion that needs to
be tested with fresh human TILs from melanoma samples.
In this study, we assessed the expression of PD-1 on CD4þ and
CD8þ TILs freshly isolated from primary and metastatic cutaneous
melanomas, and the expression of PD-1 ligands in these tumor
tissues. We also examined early T-cell responses of TILs directly
ex vivo, by flow cytometry and video imaging. We propose a
comprehensive interpretation of this original set of data.
RESULTS
PD-1 is progressively expressed on CD4 and CD8 T cells
infiltrating primary and metastatic melanoma lesions
The expression of PD-1 was analyzed on fresh TILs isolated
from melanoma tissue samples. The characteristics of patient
population are listed in Table 1. Primary tumors (n¼17) and
cutaneous metastases (n¼18) were collected at the time of
surgery and immediately dissociated for ex vivo analysis. PD-1
was found to be expressed at various levels on CD4þ and
CD8þ TILs (Figure 1a). By contrast, PD-1 was hardly
detectable on peripheral blood T lymphocytes (PBLs) obtained
from patients (n¼11) or from healthy donors (n¼ 7). In most
cases, the expression of PD-1 was upregulated homogeneously
on T-cell populations (Figure 1a). In 30% of metastases and in
18% of primary lesions, PD-1 expression on CD8þ TILs was
bimodal, revealing two sub-populations with both a low and a
high PD-1 expression (Figure 1b). In these cases, the
proportion of PD-1high CD8þ TILs was quite variable (median
of 47%, range 11–72%) in both primary and metastatic lesions
(P¼ 0.44, Fisher’s exact test).
By comparing the level of PD-1 on CD4þ or CD8þ T cells in
PBLs and in primary and metastatic lesions, one can see that its
expression increases with disease progression. In primary
tumors, CD4þ TILs showed higher levels of PD-1 than did
circulating CD4þ T cells (Figure 2a). This expression was further
increased in metastatic lesions. Similarly, PD-1 was progressively
upregulated on CD8þ TILs, with an expression pattern that was
heterogeneous among patient samples in primary tumors.
PD-1high CD4þ and CD8þ TILs accumulate in advanced
primary tumors and distant cutaneous metastases
We looked more closely at PD-1 expression on TILs from
early (in situ or T1) and advanced primary melanomas
(T2/T4). Despite the small number of samples, it seems that
CD4þ and CD8þ TILs expressed higher levels of PD-1 in T2/
T4 primary lesions than did peripheral blood T cells (Figure
2b). PD-1 TIL expression was not significantly different
between Tis/T1 and T2/4 lesions, except may be for CD8 T
cells (P¼0.059, Mann–Whitney test). Upregulation of PD-1
on CD8þ TILs was also higher in thick primary tumors (with
BreslowX1mm compared with Breslowo1mm, P¼0.046,
Mann–Whitney test) and was associated with a higher level of
invasion (Clark levels of IV/V compared with Clark levels of
I–III (P¼ 0.018, Mann–Whitney test)).
The disease usually progresses from primary melanoma to
local recurrences, in transit metastasis and further dissemi-
nates to regional lymph nodes and distant metastases. We
looked at the PD-1 expression according to metastasis
localization and found that it was higher on CD4þ and
CD8þ TILs from distant metastases compared with local and
Table 1. Patient characteristics
Primary
Metastasis
(cutaneous)
Total no. 17 18
Sex
Male 8 12
Female 9 6
Age (years)
Median 69 72
Range 50–93 45–89
2009 AJCC stage
Tis 2 IIc 2
T1 7 III 3
T2 4 IV1 13
T4 4
Local 6
In transit 4
Distant 8
Previous therapy
NA Chemo 8
Disease evolution
NED 13 DF 2
Relapse 1 AWD 6
Death 1 Death 10
Abbreviations: AJCC, American Joint Committee on Cancer; AWD, alive
with disease; DF, disease free; NA, not applicable; NED, non-evidence of
disease.
1Stage IV patients analyzed for distant metastasis (n=8) or for in-transit/
local relapse (n=5).
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in-transit metastases (Figure 2c). Although the number of
samples was admittedly small (8–10 per condition), the
difference was statistically significant (Po0.05).
PD-1 ligands are expressed on fresh tumoral cells and on
tumor-derived myeloid cells
We first used paraffin-embedded tissue sections to look at PD-L1
expression in situ on primary melanomas (n¼ 7) and cutaneous
metastases (n¼ 14). We failed to detect a substantial expression
of PD-L1 on tumor cells, which contrasts with positivity that we
have observed in other tumor types (Badoual et al., personal
communication). We could only note a PD-L1 positivity on
pigmented melanophages in two cutaneous metastases. The
expression of PD-L1 and PD-L2 was further investigated by flow
cytometry on both tumor cells (CD45) and myeloid cells
(CD45þ SSChigh) freshly isolated from tumor biopsies. On the
limited number of primary tumors with sufficient cells available
for flow cytometry (n¼ 4), PD-1 ligands were not detected,
except in one case, which was a partially regressing tumor that
we will describe below. In cutaneous metastases, PD-L1 and
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Figure 1. PD-1 is expressed at various levels on TILs from primary and
metastatic cutaneous lesions. PD-1 expression was determined by flow
cytometry on freshly isolated CD4þ and CD8þ TILs. (a) Representative
profiles of TILs isolated from primary tumor (Prim) and metastatic cutaneous
lesions (Meta) are shown. For comparison, the profile of PD-1 expression
on T cells from PBL is shown. (b) In some tumor biopsies (3/17 primary tumors
and 6/18 metastatic lesions), a subset of CD8þ TILs expresses a high
level of PD-1. A typical example of TILs isolated from a metastasis is
shown. PBL, peripheral blood T lymphocyte; PD-1, programmed death-1;
TILs, tumor-infiltrating T lymphocytes.
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Figure 2. Upregulation of PD-1 expression in primary and metastatic
lesions. (a) PD-1 expression on CD4þ and CD8þ T cells from PBLs (n¼ 18),
primary cutaneous melanomas (n¼ 17), and cutaneous metastases (n¼18) is
shown. The expression of PD-1 was different on CD4þ and CD8þ T cells
between PBL, primary tumors, and cutaneous metastases (Kruskal–Wallis test),
with a higher expression of PD-1 on TILs from primary and cutaneous
metastases (Mann–Whitney). (b) PD-1 expression on PBL, Tis/T1, and T2/T4
primary tumors. The expression was higher in T2/T4 primary tumors than in
PBL (Kruskal–Wallis and Dunn’s multiple comparison test), but the difference
was not significant between Tis/T1 and T2/T4. (c) The expression of PD-1 on
TILs from local/in-transit and distant metastases. The expression was higher in
distant than in local/in-transit metastases (Mann–Whitney). *Po0.05,
**Po0.01, ***Po0.001. Meta, metastatic cutaneous lesion; MFI, mean
fluorescence intensity; PBL, peripheral blood T lymphocyte; PD-1,
programmed death-1; Prim, primary tumor; TILs, tumor-infiltrating T
lymphocytes.
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PD-L2 could be detected in approximately 60–70% of the cases
(Table 2). PD-L1 was frequently expressed at the cell surface of
both tumoral and tumor-derived myeloid cells, whereas PD-L2
was almost exclusively found on myeloid cells.
Thus, in melanoma, the expression of PD-1 ligands may be
considered as a feature more typical of metastatic lesions.
PD-1þ TILs have impaired TCR signaling
As freshly isolated TILs frequently expressed the inhibitory
receptor PD-1, we assessed whether these lymphocytes
responded to TCR stimulation ex vivo. The small amount of
cells that can be isolated from melanoma cutaneous lesions
and analyzed immediately ex vivo is not compatible with
further purification of TILs for functional assays. An accurate
assay that is compatible with this constraint is the measurement
by video imaging of early Ca responses that occur in the minute
after TCR stimulation. An advantage of this readout is that it
may be performed very rapidly after TIL isolation, without
culturing cells for several hours or days; it thus reflects the
functional state in which TILs were within the tumor. However,
it does not allow distinguishing between PD-1low and PD-1high
TILs concomitantly with anti-CD3 stimulation. Nevertheless,
we could show that Ca responses measured after anti-CD3
stimulation in TILs isolated from different cutaneous melanoma
lesions were markedly reduced compared with PBL (Figure 3a).
No difference between primary melanomas (n¼3) and
cutaneous metastases (n¼ 4) could be identified (peak Ca ratio
of 1.11±0.07 vs. 1.08±0.04, respectively).
In few samples with sufficient TILs isolated from cutaneous
biopsies, we determined the capacity of CD4þ and CD8þ
TILs to produce IFN-g. As shown in Figure 3b, 14% of freshly
isolated CD8þ TILs produced IFN-g in response to anti-CD3/
anti-CD28-coated beads. Nevertheless, the vast majority
(B70%) of them responded to stimulation with PMA (phorbol
12-myristate 13-acetate)/ionomycin. These results indicate
that CD8þ TILs differentiated into effector T cells that are
capable of producing IFN-g, but most of them do not produce
this cytokine when TCR is engaged. CD4þ TILs were less
affected than were CD8þ T cells. Indeed, the proportion of
IFN-gþ CD4þ TILs was only two times lower with anti-CD3/
CD28 stimulation than with PMA/ionomycin (Figure 3b).
Taken together, these data show that PD-1þ TILs freshly
isolated from cutaneous melanoma have early signaling
defects after TCR stimulation, which obviously contribute to
decrease the capacity of these cells to produce cytokines
such as IFN-g.
PD-1þ TILs in a partially regressing primary tumor
For comparing the abundance, phenotype, and functionality
of TILs in regressing versus progressing lesions, we once had
the opportunity of having a patient who presented a partially
regressing superficial spreading melanoma, large enough to
get a biopsy of regressing area and a non-regressing adjacent
area (Figure 4a). Histological examination of the regressing
area allowed distinguishing melanoma cells with atypic
nuclei without evidence for mitotic activity, and a moderate
infiltrate of mononuclear cells in an area of fibrous tissue
with many enlarged capillaries. A few mononuclear cells
appeared in close contact with tumoral cells (Figure 4a,
Table 2. PD-L1 and PD-L2 expression in melanoma
metastasis
PD-L1 PD-L2
Total no.1 12 9
Positive biopsy 7 (58%) 6 (66%)
Tumoral cells 1 (8%) 1 (11%)
Myeloids 2 (17%) 5 (55%)
Tumoral and myeloids 4 (33%) 0
Abbreviations: PD-L1; ligand 1 of programmed death; PD-L2, ligand 2 of
programmed death.
1n=12 metastases evaluated for PD-L1 and/or PD-L2 expressions (n=9 for
PDL-1 and PDL-2; n=3 for PDL-1 only).
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Figure 3. Weak calcium response and IFN-c production by TILs ex vivo.
(a) Left: Ca response measured in TILs isolated from melanoma biopsies
(n¼7) compared with PBLs (n¼ 5). Bars correspond to mean. **Po0.01,
Mann–Whitney. Examples of responses measured by Ca imaging after anti-
CD3 stimulation (arrow) in PBLs (top) and in TILs from a melanoma (bottom).
Each trace corresponds to an average of 12–15 cells in the same microscopic
field. (b) Production of IFN-g by CD8þ and CD4þ TILs was determined
after stimulation with anti-CD3/anti-CD28-coated beads or PMA/ionomycin
stimulation. Mean±SEM of TILs from three tumor biopsies is shown.
Ca, calcium; iono, ionomycin; PBL, peripheral blood T lymphocyte;
PD-1, programmed death-1; PMA, phorbol 12-myristate 13-acetate;
TILs, tumor-infiltrating T lymphocytes.
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arrows). By flow cytometry, we observed that the regressing
lesion contained much more TILs than the other area with 51
versus 17% of CD3þ T cells (Figure 4b). Our expectation
was that TILs present in a regressing lesion might express less
PD-1 and be more functional than those present in a non-
regressing lesion. This was not the case. Indeed, in the two
areas, CD8þ and CD4þ T cells expressed similar levels of
PD-1 (Figure 4c), indicating that the ongoing immune
response in the regressing area was associated with a high
PD-1 expression on TILs. We got enough cells from the
regressing area to look at PD-L expression and TIL reactivity.
A faint expression of PD-L1 on tumor cells and expression of
PD-L2 on tumor-derived myeloid cells were also observed
(data not shown). Thus, PD-1þ TILs found in the regressing
area may still be negatively regulated by the PD-1/PD-L
pathway. Despite the large infiltration by TILs (Figure 4b), the
anti-CD3-induced Ca response in these TILs was still very
weak (Figure 4d), indicating that tumor regression does not
necessarily correlate with infiltration by TILs with high
responsiveness ex vivo.
DISCUSSION
This study shows that PD-1 is expressed, although at low levels,
on T cell-infiltrating primary cutaneous melanomas, its expres-
sion being further increased on TILs found in distant metastases.
These PD-1þ TILs are weakly reactive ex vivo as demonstrated
by their low Ca response to anti-CD3 stimulation, not only in
progressing tumors but also in a regressing tumor.
The presence of CD8þ T cells in primary melanoma has
been associated with a favorable outcome, especially when
they express CD69 (Hillen et al., 2008). This suggests that the
existence of tumor-specific T cells (susceptible to be trapped in
an antigen-specific manner in tumors) may influence the
evolution of the disease. This does not mean that these cells are
the main actors, or are even significantly involved in tumor
regression. Their control of the disease may well be exerted
outside primary lesions, for instance, by slowing the develop-
ment of metastases (Lengagne et al., 2008; Eyles et al., 2010).
Indeed, within the tumor microenvironment, these cells appear
poorly reactive to TCR stimulation. The exact status of intra-
tumoral T cells deserves to be further clarified.
Programmed death-1 being a marker of recently activated
T cells, the small PD-1 expression that is observed on CD8þ
and CD4þ TILs present in primary tumors, especially those
corresponding to the T2/T4 stage, reveals that some T-cell
activation occurs in these tumors. In tumors that showed a
bimodal expression of PD-1 on CD8þ TILs, one can make
the hypothesis that only high expressors were tumor antigen
specific, whereas low expressors would be passengers,
recruited by inflammatory chemokines but not antigen
specific. More generally, it is conceivable that tumors with
R
NR
SS
C 51% 17%
NRR
CD3
1,000
800
600
400
200
100
100
80
60
40
20
0
100
80
60
40
20
0
101 102 103 104 100 101 102 103 104
CD4
R
CD8
R
CD8
NR
CD4
NR
PD-1
1.6
0 200 400 600
1
1.3
Ce
ll n
u
m
be
r
Ca
 ra
tio
Time (s)
d
Figure 4. Expression of PD-1 and weak reactivity of TILs from a regressing
primary melanoma. (a) Regressing (R) and non-regressing (NR) areas from a
primary melanoma: left: macroscopic picture, lesions of 1–2 cm wide each;
right: histology of the regressing melanoma (left, bar¼ 100mm; right,
bar¼ 50 mm). Arrows point to small immune cells interacting with large tumor
cells. (b) FACS profile showing a larger CD3þ infiltrate in the regressing
lesion (left, R) compared with the adjacent non-regressing area (right, NR).
(c) CD4þ and CD8þ TILs expressed similar levels of PD-1 in R (top) and NR
(bottom) areas. (d) The anti-CD3-induced average Ca response of 12 TILs from
the regressing lesion was delayed and blunted. Arrow: anti-CD3 addition.
Ca, calcium; PBL, peripheral blood T lymphocyte; PD-1, programmed
death-1; TILs, tumor-infiltrating T lymphocytes.
1304 Journal of Investigative Dermatology (2011), Volume 131
M Chapon et al.
PD-1 and Reactivity of Melanoma-Infiltrating T Cells
the highest PD-1 expression on TILs are those in which the
proportion of antigen-specific TILs is also the highest.
However, this activation seems to be incomplete, as it has
been reported that these TILs poorly express other activation
markers such as CD25 and OX40, especially in thick primary
tumors (Ladanyi et al., 2004). PD-1 expression is not only a
marker of partial T-cell activation, it is also likely to
contribute to inhibit T-cell signaling. With melanoma-derived
TILs, we could not directly correlate the degree of TIL
unresponsiveness with the levels of PD-1 expression because
of the limited number of samples that can be analyzed
directly ex vivo from melanoma cutaneous biopsies, but we
have addressed this point in detail on non-small-cell lung
carcinoma primary tumors (Wang et al., 2011). In addition, in
renal cell carcinoma, the expression of PD-1 on immune cells
is associated with larger tumors and frequent metastasis in
lymph nodes (Thompson et al., 2007). This does not mean
that PD-1 expression is the main cause of TIL anergy. Indeed,
other molecules (such as transforming growth factor-b,
lymphocyte activation gene 3) or cells (T regulatory)
associated with TIL dysfunction have been described, which
may explain why we observed that even TILs expressing low
levels of PD-1 could be dysfunctional. The fact that the
absence of granzyme B expression by immune cells in
primary lesions is associated with frequent metastasis in
sentinel lymph nodes (van Houdt et al., 2009) supports the
idea that early alterations of TIL functions facilitate dissemi-
nation of metastases to draining lymph nodes.
Further information regarding the functional status of TILs
may be deduced from heterogeneity in the expression of the
ligands of PD-1, namely PD-L1 and PD-L2. Although other
authors have reported PD-L1 expression in a fraction of
primary melanomas (Hino et al., 2010), in such tumors, we
did not observe a conspicuous expression of PD-L1 on tumor
cells in primary tumor sections. By flow cytometry on
dissociated tumors, there was one exception, on a partially
regressing tumor that showed a weak expression of PD-L1
and PD-L2. It is possible that PD-1 ligands were upregulated
in this particular case because of an inflammatory micro-
environment. Interestingly, a study conducted on primary
uveal melanoma (Yang et al., 2008) also failed to detect PD-
L1 expression in situ, although tumor cells strongly upregu-
late PD-L1 (and not PD-L2) in the presence of IFN-g.
Both PD-L1 and PD-L2 were expressed in cutaneous
melanoma metastases. The fact that PD-L1 and PD-L2 were
not expressed on primary melanomas that we have analyzed
shows that this expression is not a common intrinsic property
of tumor cells. We propose that it could rather be a
consequence of a poorly efficient anti-tumor immune
response. We have shown that the ability of ex vivo TILs to
secrete IFN-g is low, but not null. Thus, it is likely that these
TILs, which have been activated in vivo (as judged by their PD-
1 expression), have secreted small amounts of IFN-g, sufficient
to trigger PD-L1 expression by tumor cells. This process may
be so slow and progressive that PD-L1 expression is mainly
observed in metastatic melanoma lesions. In such tumors, TIL
stimulation continues to take place, as judged by the large
expression of PD-1 frequently observed there, together with
CD69 (data not shown). Thus, the expression of PD-1 and PD-
L1 in metastatic melanoma lesions could be considered as
witnesses of the unsuccessful response of the immune system
against the tumor. These results also support the notion that
inhibiting the PD-1/PD-L1 pathway, as recently investigated
with blocking anti-PD-1 (Brahmer et al., 2010), is a potential
target for metastatic melanoma.
Although PD-1 expression by TILs isolated from visceral
metastasis in melanoma has already been reported (Ahmad-
zadeh et al., 2009), the discussion above shows that a deeper
understanding may be obtained by comparing PD-1 and PD-
L1 expressions in primary tumors and metastases. Even more
information may be drawn from the comparison between a
progressing and a regressing part of a primary melanoma.
According to a common scheme, cytotoxic TILs are expected
to have a major role in the anti-tumor effect of the immune
system. In such a scheme, one would predict that TILs present
in a regressing tumor should be submitted to a smaller PD-1-
inhibitory effect (i.e., express less PD-1 than TILs from
progressing lesions), and seem more functional, i.e., show a
larger anti-CD3-induced Ca response than TILs obtained from
progressing tumors. Most of the TILs that we analyzed were
obtained from tumors showing no sign of regression, except
one that was clearly partially regressing. This tumor showed a
large infiltration by CD3þ T cells, and we could detect
few lymphocytes close to tumor cells as reported earlier
(Mackensen et al., 1994; Dudley et al., 2002). In our study,
we could assess the reactivity of TILs directly ex vivo and not
after in vitro culture. Unexpectedly, TILs from the regressing
biopsy expressed substantial levels of PD-1, and their Ca
responses were very weak. One may propose two interpreta-
tions for this finding. One is that TILs in the regressing lesion
were still anergic because of inflammation that sustains the
expression of PD-1 and PD-1 ligands, but this weakness was
somehow compensated by the TIL number, allowing this
enlarged cell population to contribute directly or indirectly to
tumor regression. An alternative explanation is that PD-1
expression on at least a fraction of these TILs reflected their
recent activation, which may have resulted in a transiently
desensitized state, distinct from a deeply anergic state. In
practice, such a distinction would be extremely difficult to
establish, given the multiplicity of factors acting on the
functional state of TILs and of the other immune cells having
infiltrated the tumor. Anyway, the case of spontaneous
regression reported in this study calls for more data of that
type to get a global view of the functional status of TILs and
other immune cells in regressing tumors.
In conclusion, we have shown that the level of PD-1
expression on TILs in melanoma is correlated with the
progress of the disease, from primary to metastatic stage. The
expression of PD-1 and PD-L1 in metastatic melanoma
lesions could be considered at least as witnesses of the
unsuccessful response of the immune system against the
tumor. A direct involvement of PD-1 in the severity of the
disease is suggested by the existence of clinical responses in
patients treated with an anti-PD-1 antibody (Brahmer et al.,
2010), but its relative importance, compared with other
factors contributing to TIL anergy, remains to be established.
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MATERIALS AND METHODS
Patients and samples
The samples were prospectively collected in two hospitals (Cochin
and Bichat Hospitals, Paris, France). The study protocol was
approved by the CPP Ile de France ethics committee and was
performed according to the Declaration of Helsinki Principles.
Patients who had to be treated surgically for a primary melanoma or
a cutaneous melanoma metastasis were informed of the objectives of
the study and signed a written consent before inclusion. Patients
were included if the size of the primary tumor was large enough to
allow both an adequate pathological analysis and to spare a fresh
tumor sample for the research program. Cutaneous metastases were
also divided in two parts: one for routine pathological analysis and
the other for research analysis. Altogether 17 primary melanomas
and 18 cutaneous metastases were collected.
Isolation of PBLs and TILs
Peripheral blood lymphocytes from healthy donors (Etablissement
Franc¸ais du Sang, Paris, France, n¼ 7) and from melanoma patients
(n¼ 9 with primary melanoma and n¼ 2 with metastatic melanoma)
were isolated by Ficoll gradient (Ficoll-Paque Plus, Amersham
Biosciences, GE Healthcare, Europe GmbH, Saclay, France).
For isolation of TILs, fresh tumor biopsies were dissociated
immediately after surgical resection. Single cell suspensions were
prepared by mechanical dissociation, followed by incubation with
collagenase D and DNAse enzymes Roche (Meylan, France) in RPMI
without serum (30minutes at 371C). Cell suspensions were then
filtered (100mm), rinsed with phosphate-buffered saline, 5% fetal
calf serum, and 0.5mM EDTA. TIL suspensions were further enriched
by Ficoll centrifugation when sufficient cells were available. Cells
were resuspended in complete RPMI (RPMI supplemented with 10%
AB serum, L-glutamine, HEPES, and penicillin/streptomycin) and
immediately used for flow cytometry and functional assays.
Flow cytometry for PD-1 and PD-1 ligand expression
Cell suspensions (2.105 cells per test sample) were washed in
complete RPMI and were stained with (1) anti-CD8-FITC, anti-CD4-
APC, anti-CD3-PerCP, anti-PD-1-PE, or IgG1-PE (all obtained from
BD Pharmingen, Le Pont-de-Claix, France) to determine the level of
PD-1 expression. The level of PD-1 on CD4þ or CD8þ live CD3þ
cells is expressed as the ratio between mean fluorescence intensity
(MFI) with specific anti-PD-1 mAb and MFI of the control isotype; (2)
for the expression of PD-1 ligands, cell suspensions were incubated
with complete RPMI for 15minutes at þ 41C before addition of anti-
CD45-FITC, anti-CD3-PerCP, anti-PD-L1-PE, anti-PD-L2-APC, or
IgG1-PE and IgG1-APC mAb (BD Pharmingen). Positive staining for
PD-L1 and PD-L2 was determined on CD45neg (tumor) cells and on
CD45þ sschigh (myeloid) cells by comparing the MFI with specific
mAb compared with the MFI with the respective control isotype.
After incubation with mAbs, cell suspensions were incubated for
30minutes at þ 41C with mAb, washed twice in phosphate-buffered
saline, and fixed in PFA 1%. Cells were acquired on a FACSCalibur
(BD Pharmingen) and analyzed using FlowJo flow cytometry analysis
software (Tree Star, Ashland, OR).
Ca measurements
For imaging experiments, Ca responses were measured as described
previously (Delon et al., 1998). In brief, T cells were loaded with
0.5 mM Fura-2/AM (Molecular Probes, Invitrogen, Cergy Pontoise,
France) for 15minutes at 371C in mammalian saline. T cells were
stimulated with 10 mgml1 anti-CD3 (UCHT1). Images were
acquired at 371C every 5 seconds on a Nikon microscope (Nikon,
Champigny-Sur-Marne, France) (TE300 or TE2000), with a  10 or
 20 objective. Cells were excited alternatively at 350 and 380 nm
and emissions at 510 nm were used to measure Ca variations using
Metafluor software (Molecular Devices, Roper Scientific, Evry,
France). Ca levels are represented as a ratio 350/380 fluorescence
intensity normalized to the ratio at t0.
Intracellular cytokine staining
Cell suspensions (4 105 cells per well) were incubated in a 96-well
U-bottom plate with anti-CD3/anti-CD28-coated beads (1 bead for
5 cells, Dynal, Invitrogen) or PMA (25 ngml1) and ionomycin
(5mgml1) in the presence of Brefeldin A (2mgml1, Sigma-Aldrich
Chimie SARL, Saint-Quentin-Fallavier, France). After overnight
incubation, cells were washed in phosphate-buffered saline, 2%
fetal calf serum, and stained for detection of cell surface markers and
intracellular cytokines using the IntraStain kit (BD Pharmingen) as
recommended by the manufacturer. Cells were stained with
anti-CD8-FITC and anti-CD3-PerCP for 15minutes at room tem-
perature, fixed, and permeabilized. Cells were stained with
anti-IFNg-APC (BD Pharmingen) for 30minutes at room tempera-
ture. After washing, cells were fixed with PFA 1% and stored at
þ 41C until acquisition.
Histology
Sections of 4mm thickness were obtained from biopsy specimens
fixed in 10% phosphate-buffer formalin. The sections were stained
by hematoxylin and eosin (Merck, Chimie SAS, Fontenay Sous Bois,
France) and images were analyzed using a Leitz microscope
(Leica Microsystems, Nanterre, France). For PD-L1 staining, paraffin
sections were mounted on poly-L-lysine-coated glass slides and
deparaffinized. Rehydrated sections were then pretreated with EDTA
solution (pH 9.0). Anti-PD-L1 3.1 mAb (kindly provided by D Olive,
France) was used with the automatic advanced staining module
(Nexes, Ventana, Tuscon, AZ). Slides were evaluated under a
conventional light microscopy. Tissues from head and neck
squamous cell carcinoma were used as positive controls.
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